Westpac Banking Corp decreased its stake in shares of Iqvia Holdings Inc (NYSE:IQV) by 13.5% during the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 52,915 shares of the medical research company’s stock after selling 8,235 shares during the quarter. Westpac Banking Corp’s holdings in Iqvia were worth $7,612,000 at the end of the most recent reporting period.
Other institutional investors also recently made changes to their positions in the company. C J Advisory Inc purchased a new position in Iqvia during the first quarter worth approximately $27,000. Baystate Wealth Management LLC purchased a new position in Iqvia during the first quarter worth approximately $27,000. Parkside Financial Bank & Trust lifted its position in Iqvia by 140.2% during the first quarter. Parkside Financial Bank & Trust now owns 209 shares of the medical research company’s stock worth $30,000 after buying an additional 122 shares in the last quarter. Berman Capital Advisors LLC purchased a new position in Iqvia during the fourth quarter worth approximately $46,000. Finally, ERTS Wealth Advisors LLC purchased a new position in Iqvia during the fourth quarter worth approximately $46,000. Hedge funds and other institutional investors own 89.78% of the company’s stock.
In other news, insider Ari Bousbib sold 96,000 shares of Iqvia stock in a transaction on Monday, March 25th. The stock was sold at an average price of $140.96, for a total value of $13,532,160.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael J. Evanisko sold 1,193 shares of Iqvia stock in a transaction on Monday, April 1st. The shares were sold at an average price of $144.95, for a total value of $172,925.35. The disclosure for this sale can be found here. Insiders sold 143,273 shares of company stock valued at $20,066,890 over the last ninety days. Insiders own 6.00% of the company’s stock.
Shares of NYSE IQV traded up $0.98 during trading on Friday, reaching $142.06. The stock had a trading volume of 31,976 shares, compared to its average volume of 1,095,984. Iqvia Holdings Inc has a fifty-two week low of $97.64 and a fifty-two week high of $146.10. The company has a current ratio of 1.14, a quick ratio of 1.14 and a debt-to-equity ratio of 1.69. The stock has a market capitalization of $27.83 billion, a PE ratio of 27.75, a PEG ratio of 1.70 and a beta of 0.77.
Iqvia (NYSE:IQV) last issued its quarterly earnings data on Wednesday, May 1st. The medical research company reported $1.53 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.41 by $0.12. Iqvia had a return on equity of 15.08% and a net margin of 2.35%. The business had revenue of $2.68 billion during the quarter, compared to analysts’ expectations of $2.67 billion. During the same period in the previous year, the firm posted $1.34 earnings per share. The company’s revenue was up 4.7% on a year-over-year basis. On average, equities analysts predict that Iqvia Holdings Inc will post 5.88 earnings per share for the current year.
A number of equities analysts recently commented on IQV shares. TheStreet downgraded Iqvia from a “b” rating to a “c+” rating in a research report on Wednesday, May 1st. Piper Jaffray Companies lifted their target price on Iqvia to $148.00 and gave the company a “neutral” rating in a research report on Friday, February 15th. Svb Leerink assumed coverage on Iqvia in a research report on Tuesday, May 28th. They issued an “outperform” rating and a $160.00 target price on the stock. Zacks Investment Research upgraded Iqvia from a “sell” rating to a “hold” rating in a research report on Friday, May 3rd. Finally, UBS Group set a $170.00 target price on Iqvia and gave the company a “buy” rating in a research report on Friday, February 15th. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $147.02.
WARNING: This piece was originally posted by Zolmax and is owned by of Zolmax. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://zolmax.com/investing/westpac-banking-corp-has-7-61-million-position-in-iqvia-holdings-inc-nyseiqv/3114350.html.
IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Story: What is a conference call?
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Iqvia Holdings Inc (NYSE:IQV).
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.